Latest News and Press Releases

Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.

Science 37 announces the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research.

Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.

Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.

Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.

Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.

Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.

Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial.

Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.